SLI
2.083,81
PKT
-1,26
PKT
-0,06
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 08.07.22 | Holcim Neutral | JP Morgan Chase & Co. | |
| 08.07.22 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 08.07.22 | Swiss Re Neutral | JP Morgan Chase & Co. | |
| 08.07.22 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 08.07.22 | Givaudan Neutral | Goldman Sachs Group Inc. | |
| 08.07.22 | Richemont Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.07.22 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
| 07.07.22 | Roche Hold | Jefferies & Company Inc. | |
| 07.07.22 | ams-OSRAM Hold | Jefferies & Company Inc. | |
| 06.07.22 | Swiss Re Sector Perform | RBC Capital Markets | |
| 06.07.22 | UBS Sector Perform | RBC Capital Markets | |
| 06.07.22 | UBS Outperform | RBC Capital Markets | |
| 06.07.22 | UBS Hold | Jefferies & Company Inc. | |
| 06.07.22 | UBS Buy | Jefferies & Company Inc. | |
| 06.07.22 | Swiss Re Hold | Jefferies & Company Inc. | |
| 06.07.22 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 05.07.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 05.07.22 | UBS Neutral | UBS AG | |
| 05.07.22 | Richemont Outperform | RBC Capital Markets | |
| 05.07.22 | UBS Underweight | JP Morgan Chase & Co. | |
| 05.07.22 | UBS Overweight | JP Morgan Chase & Co. | |
| 04.07.22 | Givaudan Neutral | UBS AG | |
| 04.07.22 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 04.07.22 | ams-OSRAM Neutral | JP Morgan Chase & Co. | |
| 01.07.22 | UBS Outperform | RBC Capital Markets | |
| 01.07.22 | UBS Sector Perform | RBC Capital Markets | |
| 01.07.22 | Novartis Neutral | UBS AG | |
| 01.07.22 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 01.07.22 | UBS Outperform | Credit Suisse Group | |
| 01.07.22 | Holcim Hold | Jefferies & Company Inc. | |
| 01.07.22 | Zurich Insurance Overweight | Barclays Capital | |
| 01.07.22 | Swiss Re Equal Weight | Barclays Capital | |
| 30.06.22 | Givaudan Neutral | Goldman Sachs Group Inc. | |
| 30.06.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 29.06.22 | Givaudan Hold | Deutsche Bank AG | |
| 29.06.22 | UBS Hold | Deutsche Bank AG | |
| 29.06.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 29.06.22 | Givaudan Underperform | Jefferies & Company Inc. | |
| 29.06.22 | Novartis Sell | Deutsche Bank AG | |
| 29.06.22 | UBS Neutral | Goldman Sachs Group Inc. |